IPIX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:46):

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective...

Stats
Dagens volum	21 062.00
Gjennomsnittsvolum	546 157
Markedsverdi	1.08M
EPS	$0 ( 2024-04-12 )
Neste inntjeningsdato	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.210
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-12-30	Ehrlich Leo	Sell	11 307 527	Class B Common Stock
2021-10-10	Harness Jane A.	Buy	500 000	Stock Option
2020-09-11	Harness Jane A.	Buy	58 394	Class A Common Stock
2019-09-01	Harness Jane A.	Buy	58 394	Class A Common Stock
2020-09-11	Harness Jane A.	Sell	21 606	Class A Common Stock

INSIDER POWER
-100.00
Last 91 transactions
Buy: 118 435 245 \| Sell: 65 639 262

Innovation Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Innovation Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-373 000 (0.00 %)
EPS:	$-0.00630

FY	2023
Omsetning:	$0
Bruttogevinst:	$-373 000 (0.00 %)
EPS:	$-0.00630

FY	2022
Omsetning:	$18 000.00
Bruttogevinst:	$-364 000 (-2 022.22 %)
EPS:	$-0.0142

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0400

Financial Reports:

No articles found.

Innovation

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company is also developing Kevetrin, an anti-cancer compound for treating ovarian cancer. It has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.